1                Consequently, both short- and intermediate-acting insulin analogs are under developmen

2 aceutical sector as, to our knowledge, novel intermediate-acting insulin analogs because of their sui

3 lin analogues (a mixture of rapid-acting and intermediate-acting insulin analogues) with other antidi

4 pared 133 kidney transplant recipients given intermediate-acting insulin isophane for postoperative a

5 ntersubject variability of response than the intermediate-acting insulin suspension Humulin L (Lilly,